Erbb2 mrna expression and response to ado-trastuzumab emtansine (T-dm1) in her2-positive breast cancer

Gaia Griguolo, Fara Brasó-Maristany, Blanca González-Farré, Tomás Pascual, Núria Chic, Tamara Saurí, Ronald Kates, Oleg Gluz, Débora Martínez, Laia Paré, Vassilena Tsvetkova, David Pesantez, Maria Vidal, Barbara Adamo, Montserrat Muñoz, Patricia Galván, Laura Barberá, Miriam Cuatrecasas, Mathias Christgen, Hans KreipeInés Monge-Escartín, Patricia Villagrasa, Dolors Soy, Tommaso Giarratano, Maria Vittoria Dieci, Pierfranco Conte, Nadia Harbeck, Valentina Guarneri, Aleix Prat

Research output: Contribution to journalArticlepeer-review

Abstract

Trastuzumab emtansine (T-DM1) is approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive (HER2+) metastatic breast cancer (BC) and for residual disease after neoadjuvant therapy; however, not all patients benefit. Here, we hypothesized that the heterogeneity in the response seen in patients is partly explained by the levels of human epidermal growth factor receptor 2 gene (ERBB2) mRNA. We analyzed ERBB2 expression using a clinically applicable assay in formalin-fixed paraffin-embedded (FFPE) tumors (primary or metastatic) from a retrospective series of 77 patients with advanced HER2+ BC treated with T-DM1. The association of ERBB2 levels and response was further validated in 161 baseline tumors from the West German Study (WGS) Group ADAPT phase II trial exploring neoadjuvant T-DM1 and 9 in vitro BC cell lines. Finally, ERBB2 expression was explored in 392 BCs from an in-house dataset, 368 primary BCs from The Cancer Genome Atlas (TCGA) dataset and 10,071 tumors representing 33 cancer types from the PanCancer TCGA dataset. High ERBB2 mRNA was found associated with better response and progression-free survival in the metastatic setting and higher rates of pathological complete response in the neoadjuvant setting. ERBB2 expression also correlated with in vitro response to T-DM1. Finally, our assay identified 0.20–8.41% of tumors across 15 cancer types as ERBB2-high, including gastric and esophagus adenocarcinomas, urothelial carcinoma, cervical squamous carcinoma and pancreatic cancer. In particular, we identified high ERBB2 mRNA in a patient with HER2+ advanced gastric cancer who achieved a long-lasting partial response to T-DM1. Our study demonstrates that the heterogeneity in response to T-DM1 is partly explained by ERBB2 levels and provides a clinically applicable assay to be tested in future clinical trials of breast cancer and other cancer types.

Original languageEnglish
Article number1902
Pages (from-to)1-15
Number of pages15
JournalCancers
Volume12
Issue number7
DOIs
Publication statusPublished - Jul 14 2020

Keywords

  • Antibody-drug conjugates
  • ERBB2 mRNA
  • HER2-positive breast cancer
  • T-DM1

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Erbb2 mrna expression and response to ado-trastuzumab emtansine (T-dm1) in her2-positive breast cancer'. Together they form a unique fingerprint.

Cite this